The Clinical Effect of Pregabalin on Neuropathic Pain in Non Central Sensitized Patients After Total Knee Arthroplasty

T

The Catholic University of Korea

Status

Not yet enrolling

Conditions

Osteoarthritis

Treatments

Drug: Pregabalin 150mg

Study type

Interventional

Funder types

Other

Identifiers

NCT05322681
KC22MISI0176

Details and patient eligibility

About

In this study, patients scheduled to undergo total knee arthroplasty (TKA) will be screened through a survey for patients without central sensitivity and patients with neuropathic pain as preoperative evaluation. It is designed to evaluate the effectiveness of pregabalin by dividing patient groups according to non central sensitization and neuropathic pain.

Full description

Screening for central sensitization and neuropathic pain will be performed two weeks in advance of surgery for patients scheduled to undergo total knee arthroplasty, and is performed through a central sensitization questionnaire and neuropathic pain survey. Through the Central Sensitization Inventory, if the score is 40 or lower, it is considered as the subject of non central sensitization. And 13 or higher based on 38 points are considered as the subject of neuropathic pain. Among the patients who meet these two criteria, only those who agree to the study are targeted. The same probability is assigned by a randomized table two weeks before surgery to a group taking pregabalin and a group taking no pill. In the case of patients with non-central sensitization and neuropathic pain, the experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The experimental group takes one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner. The control group takes no pill. A total of 10 weeks' worth of drugs will be provided two weeks before surgery, and medication compliance will be evaluated based on the number of unused drugs returned by the test subject when the drug is returned. In order to evaluate medication compliance, clinical trials should record the number of drugs provided and returned at each visit and the discontinuation date. Subjects must receive medication guidance on the drug-taking schedule. When the clinical trial is completed or terminated in the middle, the unused or partially used drugs must be returned to the clinical examiner and discarded after confirmation. Relief drugs can also be taken up to six tablets a day, up to two tablets of 650 mg of Tylenol ER Tablets(acetaminophen) once in both groups. Anthropological information (gender, age, weight, height, body mass index) and outcome variables (VAS scale for checking the degree of pain) are analyzed for the subjects of the study among patients with neuropathic pain. The subjects will be collected for three months after surgery in both the experimental group and the control group, and the data will be organized and the results will be derived after the last subject's three-month collection. From immediately after surgery to three months after surgery, we will evaluate the side effects complaining in the subject group. Side effects will be evaluated through interviews with patients during outpatient visits. The above clinical evaluation is observed during the daily treatment process, and the method performed in this clinical trial is judged to have no unpredictable side effects during the current clinical process.

Enrollment

90 estimated patients

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients for total knee arthroplasty over the age of 19
  • Patients who have the will or ability to follow the doctor's instructions, including rehabilitation treatment such as joint exercise.
  • Patients understand this study and agree in writing by the patient's own or by the patient's representative to participate in the study.
  • Patients with non central sensitization and neuropathic pain.

Exclusion criteria

  • Rheumatoid arthritis
  • Other inflammatory arthritis
  • Neuropsychiatric patients
  • Hepatic insufficiency
  • Renal insufficiency
  • Allergy or intolerance to study medications
  • Patients with an acetylsalicylic acid of IV (angina, congestive heart failure, dementia, cerebrovascular accident)
  • Chronic gabapentin or pregabalin use (regular use for longer than 3 months)
  • Chronic opioid use (taking opioids for longer than 3 months)
  • Alcohol, drug abuser
  • Narcotics addiction

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

90 participants in 2 patient groups

Pregabalin
Experimental group
Description:
Experimental group will take medicine for 10 weeks from 2 weeks before surgery to 8 weeks after surgery. The group takes one pill of pregabalin 150mg after breakfast and one pill of pregabalin 150 mg after dinner.
Treatment:
Drug: Pregabalin 150mg
Active Comparator
No Intervention group
Description:
Active Comparator group will take no medicine

Trial contacts and locations

1

Loading...

Central trial contact

Yong In, MD, PhD; Mansoo Kim, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems